泌尿生殖医学系合作研究与授权协议（2016-2026）

本报告分析了泌尿生殖领域的 316 项合作研究和许可协议，清楚地、以证据为基础地展示了整个市场伙伴关係的设计、谈判和执行。

目录

执行摘要

第一章：引言

第二章：泌尿生殖医学合约的发展趋势

• 介绍
• 过去几年泌尿生殖医学科室的合作
• 泌尿生殖系统协作：依合约类型
• 泌尿生殖系统协作：依产业部门划分
• 泌尿生殖医学科室间的合作：依发展阶段划分
• 泌尿生殖系统协作：依技术类型划分
• 泌尿生殖科室间的合作：依疾病分类的治疗适应症。

第三章 泌尿生殖医学合作中的财务合约条款

• 介绍
• 泌尿生殖系统合作的已揭露财务条款与条件
• 泌尿生殖系统合作的主要金额
• 泌尿生殖医学合约预付款
• 泌尿生殖医学合约的里程碑付款
• 泌尿生殖医学的权利金费率

第四章：泌尿生殖医学科的主要合约与承包公司

• 介绍
• 泌尿生殖系统合作领域最积极主动的公司
• 泌尿生殖医学领域最活跃合约公司名单
• 按金额排名的泌尿生殖医学合同

第五章：泌尿生殖科的合约记录

• 介绍
• 泌尿生殖医学合作协议（书面形式）。

第六章：泌尿生殖医学中的合约：依治疗目标划分

• 介绍
• 合约：透过泌尿生殖系统治疗目标
• 合约记录
• 合约记录 - 泌尿生殖医学合约：依公司分类 (AZ)
• 合约记录 - 泌尿生殖医学合约：依技术类型分类
• 合约类型的定义
• 关于 Biopharma Research Ltd.
• Current Partnering
• Current Agreements
• 理想合作伙伴近期报告标题

The definitive benchmark for genitourinary dealmaking

Genitourinary partnering spans a range of oncology and non-oncology indications, with deal structures reflecting the diversity of development pathways, therapeutic approaches, and commercial strategies across the space.

This report provides a comprehensive and structured analysis of 316 genitourinary collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how genitourinary deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by stage, asset type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a diverse therapeutic and commercial landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within genitourinary partnerships, particularly across indications with differing clinical and commercial dynamics.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 316 genitourinary collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and technology)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for genitourinary dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how genitourinary partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in genitourinary dealmaking

• 2.1. Introduction
• 2.2. Genitourinary partnering over the years
• 2.3. Genitourinary partnering by deal type
• 2.4. Genitourinary partnering by industry sector
• 2.5. Genitourinary partnering by stage of development
• 2.6. Genitourinary partnering by technology type
• 2.7. Genitourinary partnering by therapeutic indication

Chapter 3 - Financial deal terms for genitourinary partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for genitourinary partnering
• 3.3. Genitourinary partnering headline values
• 3.4. Genitourinary deal upfront payments
• 3.5. Genitourinary deal milestone payments
• 3.6. Genitourinary royalty rates

Chapter 4 - Leading genitourinary deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in genitourinary partnering
• 4.3. List of most active dealmakers in genitourinary
• 4.4. Top genitourinary deals by value

Chapter 5 - Genitourinary contract document directory

• 5.1. Introduction
• 5.2. Genitourinary partnering deals where contract document available

Chapter 6 - Genitourinary dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by genitourinary therapeutic target
• Deal directory
• Deal directory - Genitourinary deals by company A-Z
• Deal directory - Genitourinary deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Genitourinary partnering since 2016
• Figure 2: Genitourinary partnering by deal type since 2016
• Figure 3: Genitourinary partnering by industry sector since 2016
• Figure 4: Genitourinary partnering by stage of development since 2016
• Figure 5: Genitourinary partnering by technology type since 2016
• Figure 6: Genitourinary partnering by indication since 2016
• Figure 7: Genitourinary deals with a headline value
• Figure 8: Genitourinary deals with upfront payment values
• Figure 9: Genitourinary deals with milestone payment
• Figure 10: Genitourinary deals with royalty rates
• Figure 11: Active genitourinary dealmaking activity since 2016
• Figure 12: Top genitourinary deals by value since 2016